Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 10:34 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 649–672 of 6,437 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Renal Clear all
Not yet recruiting Early Phase 1 Interventional Accepts healthy volunteers

Comparing Alkalinizing Agents Efficacy on Stone Risk in Patients on a Metabolically Controlled Diet

NCT04651088
View directory record Official record
Conditions
Kidney Stone
Interventions
Potassium citrate, Sodium bicarbonate, Litholyte, Crystal Lite, Potassium Bicarbonate
Drug · Dietary Supplement
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 90 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Feb 13, 2026 · Synced Oct 23, 2026, 10:34 AM EDT
Withdrawn No phase listed Observational

Study to Determine the Impact of Intraoperative Blood Pressure Management on Postoperative Outcomes (MAP-ALIVE)

NCT02019342
View directory record Official record
Conditions
Death, Postoperative Complications, Myocardial Infarction, Stroke, Renal Failure
Interventions
FACE quality improvement initiative (see below), Pre-quality improvement initiative
Other
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
2
States / cities
Ann Arbor, Michigan • St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jan 29, 2018 · Synced Oct 23, 2026, 10:34 AM EDT
Completed Phase 4 Interventional Results available

Pharmacokinetics of Ertapenem in Continuous Venovenous Hemodialysis

NCT00877370
View directory record Official record
Conditions
Acute Kidney Failure
Interventions
ertapenem
Drug
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Sep 28, 2012 · Synced Oct 23, 2026, 10:34 AM EDT
Completed Phase 2 Interventional

A Phase 2 Extension Study of Study GCS-100-CS-4002

NCT02155673
View directory record Official record
Conditions
Chronic Kidney Disease
Interventions
GCS-100
Drug
Lead sponsor
La Jolla Pharmaceutical Company
Industry
Eligibility
18 Years to 80 Years
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
5
States / cities
Tempe, Arizona • La Mesa, California • Denver, Colorado + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 26, 2016 · Synced Oct 23, 2026, 10:34 AM EDT
Completed Phase 4 Interventional Results available

Idiopathic Focal Segmental Glomerulosclerosis (FSGS) and Treatment With ACTH

NCT01155141
View directory record Official record
Conditions
Kidney Diseases
Interventions
H.P. Acthar Gel
Drug
Lead sponsor
Stanford University
Other
Eligibility
16 Years to 65 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Sep 1, 2014 · Synced Oct 23, 2026, 10:34 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Ibrutinib and Nivolumab in Treating Patients With Previously-Treated Metastatic Kidney Cancer

NCT02899078
View directory record Official record
Conditions
Metastatic Renal Cell Cancer, Stage IV Renal Cell Cancer
Interventions
Ibrutinib, Nivolumab
Drug
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated May 18, 2025 · Synced Oct 23, 2026, 10:34 AM EDT
Terminated Phase 4 Interventional Results available

Erector Spinae Plane Block (ESPB): in Patients Undergoing Surgery Through a Flank or Anterior Subcostal Incision.

NCT03691935
View directory record Official record
Conditions
Nephrectomy, Partial Nephrectomy, Incision Site Discomfort
Interventions
Ropivacaine, Normal saline
Drug
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
18 Years to 85 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
1
States / cities
Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 10, 2025 · Synced Oct 23, 2026, 10:34 AM EDT
Recruiting No phase listed Observational

SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

NCT03452774
View directory record Official record
Conditions
Cancer, Metastatic, Cancer, Cancer of Pancreas, Cancer of Liver, Cancer of Stomach, Cancer Liver, Cancer of Rectum, Cancer of Kidney, Cancer of Esophagus, Cancer of Cervix, Cancer of Colon, Cancer of Larynx, Cancer, Lung, Cancer, Breast, Cancer, Advanced, Cancer Prostate, Cancer of Neck, Cancer of Skin, Neuroendocrine Tumors, Carcinoma, Mismatch Repair Deficiency, BRCA Gene Rearrangement, Non Hodgkin Lymphoma, Leukemia, Non Small Cell Lung Cancer, Cholangiocarcinoma, Glioblastoma, Central Nervous System Tumor, Melanoma, Urothelial Carcinoma, Bladder Cancer, Ovarian Cancer, Endometrial Cancer, Testicular Cancer, Breast Cancer, COVID, Myelofibrosis, Myeloproliferative Neoplasm, Myeloproliferative Disorders, Follicular Lymphoma, Mantle Cell Lymphoma, Marginal Zone Lymphoma, Myelodysplastic Syndromes
Interventions
Clinical Trial Matching
Other
Lead sponsor
Massive Bio, Inc.
Industry
Eligibility
Not listed
Enrollment
50,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2040
U.S. locations
67
States / cities
Birmingham, Alabama • Mobile, Alabama • Scottsdale, Arizona + 64 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2025 · Synced Oct 23, 2026, 10:34 AM EDT
Active, not recruiting Phase 3 Interventional Results available

Study of Cabozantinib in Combination With Nivolumab and Ipilimumab in Patients With Previously Untreated Advanced or Metastatic Renal Cell Carcinoma

NCT03937219
View directory record Official record
Conditions
Renal Cell Carcinoma
Interventions
Cabozantinib, Nivolumab, Ipilimumab, Cabozantinib-matched placebo
Drug · Biological
Lead sponsor
Exelixis
Industry
Eligibility
18 Years and older
Enrollment
855 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
30
States / cities
La Jolla, California • Orange, California • Boca Raton, Florida + 23 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2026 · Synced Oct 23, 2026, 10:34 AM EDT
Completed No phase listed Observational

Prediction of 30-Day Readmission Using Machine Learning

NCT04849312
View directory record Official record
Conditions
Infection, Heart Failure, Chronic Obstructive Pulmonary Disease, Asthma, Gout Flare, Chronic Kidney Diseases, Hypertensive Urgency, Atrial Fibrillation Rapid, Anticoagulants; Increased
Interventions
Not listed
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
372 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 17, 2026 · Synced Oct 23, 2026, 10:34 AM EDT
Recruiting Not applicable Interventional

Optimizing Pulsatility During Cardiopulmonary Bypass to Reduce Acute Kidney Injury

NCT06349577
View directory record Official record
Conditions
Acute Kidney Injury, Hemolysis, Thrombocytopenia, Surgery
Interventions
Non-pulsatile blood flow, Pulsatile blood flow
Other
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 85 Years
Enrollment
1,100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated May 21, 2025 · Synced Oct 23, 2026, 10:34 AM EDT
Completed Phase 2 Interventional Results available

Does Nesiritide Provide Renal Protection

NCT01440881
View directory record Official record
Conditions
Renal Failure
Interventions
Nesiritide, Placebo
Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 80 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Jun 6, 2014 · Synced Oct 23, 2026, 10:34 AM EDT
Completed Phase 2 Interventional Results available

Testing Cabozantinib, Crizotinib, Savolitinib and Sunitinib in Kidney Cancer Which Has Progressed

NCT02761057
View directory record Official record
Conditions
Locally Advanced Papillary Renal Cell Carcinoma, Metastatic Papillary Renal Cell Carcinoma, Stage III Renal Cell Cancer AJCC v7, Stage IV Renal Cell Cancer AJCC v7, Type 1 Papillary Renal Cell Carcinoma, Type 2 Papillary Renal Cell Carcinoma, Unresectable Renal Cell Carcinoma
Interventions
Biospecimen Collection, Bone Scan, Cabozantinib S-malate, Computed Tomography, Crizotinib, Savolitinib, Sunitinib Malate
Procedure · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
152 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
586
States / cities
Anchorage, Alaska • Kingman, Arizona • Fort Smith, Arkansas + 361 more
Source: ClinicalTrials.gov public record
Updated Jan 13, 2025 · Synced Oct 23, 2026, 10:34 AM EDT
Completed Not applicable Interventional Results available

Campath-1H Induction to Allow Discontinuation of Calcineurin Inhibitors After Renal Transplantation

NCT00214201
View directory record Official record
Conditions
Primary Renal Transplant
Interventions
Calcineurin inhibitor withdrawal
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years to 75 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2009
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Oct 3, 2012 · Synced Oct 23, 2026, 10:34 AM EDT
Terminated Phase 3 Interventional

Study Comparing Sirolimus With Cyclosporine in a Calcineurin Inhibitor (CNI)-Free Regimen in Kidney Transplant Recipients

NCT00137345
View directory record Official record
Conditions
Kidney Transplant
Interventions
sirolimus
Drug
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Eligibility
13 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
23
States / cities
San Diego, California • San Francisco, California • Denver, Colorado + 18 more
Source: ClinicalTrials.gov public record
Updated Feb 8, 2013 · Synced Oct 23, 2026, 10:34 AM EDT
Completed Phase 4 Interventional Results available

Safety and Efficacy of Ingenol Mebutate Gel 0.015% for Treatment of AK on the Face in Solid Organ Transplant Recipients

NCT02866695
View directory record Official record
Conditions
Actinic Keratosis
Interventions
ingenol mebutate gel 0.015%
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Mar 9, 2022 · Synced Oct 23, 2026, 10:34 AM EDT
Completed Phase 3 Interventional Results available

The Effects of Vitamin D Repletion in Vitamin D Deficient Patients With Stage 3 and 4 Chronic Kidney Disease

NCT01029002
View directory record Official record
Conditions
Chronic Renal Insufficiency, Proteinuria
Interventions
Vitamin D, Placebo
Drug · Other
Lead sponsor
Albert Einstein College of Medicine
Other
Eligibility
18 Years and older
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Aug 16, 2023 · Synced Oct 23, 2026, 10:34 AM EDT
Active, not recruiting Phase 3 Interventional

A Study of Belzutifan (MK-6482) in Combination With Lenvatinib Versus Cabozantinib for Treatment of Renal Cell Carcinoma (MK-6482-011)

NCT04586231
View directory record Official record
Conditions
Carcinoma, Renal Cell
Interventions
Belzutifan, Lenvatinib, Cabozantinib
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
747 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
33
States / cities
Chandler, Arizona • Los Angeles, California • Orange, California + 27 more
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Oct 23, 2026, 10:34 AM EDT
Completed Phase 3 Interventional Results available

Continuous Soluble Ferric Pyrophosphate (SFP) Iron Delivery Via Dialysate in Hemodialysis Patients

NCT01320202
View directory record Official record
Conditions
Renal Failure Chronic Requiring Hemodialysis
Interventions
Soluble Ferric Pyrophosphate (SFP), Standard dialysate
Drug · Device
Lead sponsor
Rockwell Medical Technologies, Inc.
Industry
Eligibility
18 Years and older
Enrollment
305 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
45
States / cities
Bakersfield, California • Chula Vista, California • Cudahy, California + 37 more
Source: ClinicalTrials.gov public record
Updated Apr 26, 2017 · Synced Oct 23, 2026, 10:34 AM EDT
Withdrawn No phase listed Observational

Safety of Iodinated Contrast in Liver Transplant Candidates With Decreased Renal Function Undergoing Coronary CT Angiography

NCT03806725
View directory record Official record
Conditions
Acute Kidney Injury, Renal Insufficiency, Chronic, Contrast-induced Nephropathy, Liver Transplantation, Contrast Media
Interventions
Intravenous administration of iodinated contrast medium for coronary CT angiography
Diagnostic Test
Lead sponsor
Stanford University
Other
Eligibility
21 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Jan 4, 2022 · Synced Oct 23, 2026, 10:34 AM EDT
Completed No phase listed Observational

Evaluating Urinary CXCL10 for Enhanced Detection of Acute Rejection in Kidney Transplant Patients With Low DD-CFDNA

NCT07415876
View directory record Official record
Conditions
Kidney Transplant Rejection
Interventions
Retrospective Cohort Enrollment, Prospective Cohort Enrollment
Other
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Jul 15, 2026 · Synced Oct 23, 2026, 10:34 AM EDT
Completed No phase listed Observational

A Study on Patients With Chronic Kidney Disease (CKD) to Assess Treatment Experience and Patterns, Effect of the Treatment, Patient Outcomes and Patient Quality of Life

NCT04034992
View directory record Official record
Conditions
Chronic Kidney Disease
Interventions
Not listed
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
1,052 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
11
States / cities
Riverside, California • San Francisco, California • Sanford, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Mar 6, 2024 · Synced Oct 23, 2026, 10:34 AM EDT
Terminated No phase listed Observational

A Urinary Tumor Marker (Kidney Injury Molecule-1) for the Detection of Renal Cell Carcinoma

NCT01063998
View directory record Official record
Conditions
Renal Cell Carcinoma
Interventions
Urine Marker
Other
Lead sponsor
Jason Hafron
Other
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Royal Oak, Michigan
Source: ClinicalTrials.gov public record
Updated Nov 8, 2013 · Synced Oct 23, 2026, 10:34 AM EDT
Completed Phase 2 Interventional

Sequential ATRA Then IL-2 for Modulation of Dendritic Cells and Treatment of Metastatic Renal Cell Cancer

NCT00100906
View directory record Official record
Conditions
Kidney Cancer
Interventions
IL-2, ATRA
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2013
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Aug 16, 2013 · Synced Oct 23, 2026, 10:34 AM EDT